{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:42:18Z","timestamp":1761093738215,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873430"],"award-info":[{"award-number":["81873430"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bcmd.2022.102698","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T12:31:22Z","timestamp":1658320282000},"page":"102698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms"],"prefix":"10.1016","volume":"97","author":[{"given":"Jin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenya","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.bcmd.2022.102698_bb0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcmd.2022.102698_bb0010","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/asheducation-2016.1.534","article-title":"Update from the latest WHO classification of MPNs: a user\u2019s manual","volume":"2016","author":"Passamonti","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"24","key":"10.1016\/j.bcmd.2022.102698_bb0015","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2017-04-777805","article-title":"Pre-PMF emerging as mportant subgroup of MPN","volume":"129","author":"Gisslinger","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcmd.2022.102698_bb0020","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.bcmd.2022.102698_bb0025","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ajh.24788","article-title":"Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease: JERYCZYNSKI et al","volume":"92","author":"Jeryczynski","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1016\/j.bcmd.2022.102698_bb0030","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/asheducation-2016.1.534","article-title":"Update from the latest WHO classification of MPNs: a user\u2019s manual","volume":"2016","author":"Passamonti","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.bcmd.2022.102698_bb0040","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2022.102698_bb0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","article-title":"The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"Abdulkarim","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcmd.2022.102698_bb0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myelo- proliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2022.102698_bb0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1582-4934.2008.00559.x","article-title":"Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1","volume":"13","author":"Tefferi","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bcmd.2022.102698_bb0060","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2022.102698_bb0065","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2022.102698_bb0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2022.102698_bb0075","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2022.102698_bb0080","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcmd.2022.102698_bb0085","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12185-017-2246-9","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"105","author":"Imai","year":"2017","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bcmd.2022.102698_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcmd.2022.102698_bb0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcmd.2022.102698_bb0100","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcmd.2022.102698_bb0105","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcmd.2022.102698_bb0110","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcmd.2022.102698_bb0115","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcmd.2022.102698_bb0035","series-title":"Bone Marrow Pathology","article-title":"The normal bone marrow","author":"Bain","year":"2019"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979622000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979622000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:36:29Z","timestamp":1761050189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979622000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":23,"alternative-id":["S1079979622000559"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2022.102698","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The differences of hemogram, myelogram, and driver gene mutations in classic myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2022.102698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102698"}}